Early Detection and Strategies for Overcoming Therapy Resistance in Lung Cancer and Mesothelioma

Dear Colleagues,

Early detection and overcoming therapy resistance in lung cancer and mesothelioma are fundamental cornerstones for improving patient outcomes.

We welcome high-quality manuscripts exploring early detection strategies, including screening approaches, biomarker research and improved molecular diagnostics for lung cancer and mesothelioma. Overcoming resistance involves strategies such as targeting specific molecular pathways and immune responses, and exploring combinatory approaches and novel delivery systems for anti-cancer drugs.

Understanding the mechanisms of primary and acquired resistance to targeted therapies is crucial for selecting subsequent treatments. Equally important is understanding the tumour microenvironment and its influence on therapy resistance, which is essential for developing effective therapeutic strategies.

Effective management of lung cancer and mesothelioma requires a multidisciplinary approach, involving pathologists, surgeons, medical oncologists, radiation oncologists and other specialists. We encourage interdisciplinary and biomarker-driven clinical trials, which are essential for advancing treatment options and overcoming resistance in both lung cancer and mesothelioma.

Prof. Dr. Katalin Dobra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.